Mon, Sep 22, 2014, 6:29 AM EDT - U.S. Markets open in 3 hrs 1 mins

Recent

% | $
Quotes you view appear here for quick access.

InterMune, Inc. Message Board

  • b12s_slurpy b12s_slurpy Dec 31, 2010 9:37 AM Flag

    Researchers:Pirfenidone Trials FLAWED!

    They cite poor choice of patients, poor test parameters and flawed interpretation of the data.

    Calls to wait for results of Japanese
    trials requested.

    http://ajrccm.atsjournals.org/cgi/content/full/172/9/1229

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Good Read, thanks.

      We're talking about a palliative treatment. Since we're not talking about arresting the disease process, but merely slowing it, then cost/benefit is a prime consideration. So far no studies have proved that the drug makes these patients more comfortable. An increase in vital capacity is good, if it translates into a lower work of breathing. That would produce subjective relief. So far I'm not seeing convincing evidence of subjective relief.

      Pulmonary fibrosis causes ventilation/perfusion imbalance. It isn't helpful if ventilation improves in regions of the lung that are poorly perfused due to scarring. An improvement in exercise tolerance or in hemoglobin saturation would indicate an overall improvement in ventilation-perfusion ratios. The studies are not showing this result.

      No drug interaction studies have been done, so it is risky to add a drug with poorly understood action to the regimen of patients with pulmonary fibrosis because many have other medical conditions. For example doxycycline, ibuprofen, and statin drugs are photo-toxic. Does Perfenidone potentiate this action?

    • Good job, please get as many shorts as possible it will only serve as rocket fuel for the next run to 50's.

    • and this scientists was paid by ITMN
      and Shionogi in Japan for his opinion
      and still this is the BEST he can
      HONESTLY say!

      Conflict of Interest Statement: G.R. received $1,000 in 2002 from Shionogi, $500 in 2003 from Intermune as a consultant, and $2,500 in 2004 from Intermune as an Advisor for pirfenidone studies in idiopathic pulmonary fibrosis.

 
ITMN
73.85+0.15(+0.20%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Dresser-Rand Group Inc.
NYSEFri, Sep 19, 2014 4:04 PM EDT
Tesco Corporation
NasdaqGSFri, Sep 19, 2014 4:00 PM EDT